查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1866587

雙特異性抗體療法：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Bi-Specific Antibodies Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球雙特異性抗體療法市場預計在 2024 年達到 41.65 億美元，預計到 2031 年將達到 180.56 億美元，2025 年至 2031 年的複合年成長率為 23.4%。

雙特異性抗體（BsAb）或雙特異性單株抗體（BsMAb）是由兩種不同抗體的片段組成的人工合成蛋白。由於含有兩個不同的抗原結合域，雙特異性抗體可以辨識並結合兩種不同的抗原，或結契約一抗原上的兩個不同表位。

雙特異性抗體療法市場的成長受多種因素驅動，包括臨床需求的增加、技術進步、投資動能以及監管支持。其中一個關鍵促進因素是全球癌症發生率的上升，尤其是骨髓惡性腫瘤和難治性固態腫瘤，這催生了對更精準、更有效的免疫療法的強勁需求。雙特異性抗體能夠同時靶向兩種不同的抗原，從而增強特異性和免疫激活，並已成為腫瘤治療領域極具前景的下一代療法。

生物技術和抗體工程的進步顯著加速了雙特異性抗體平台的發展。過去，結構複雜性、穩定性差和生產產量低等挑戰限制了其發展。然而，蛋白質設計、表現系統和藥物傳遞技術的突破催生了臨床可行的抗體形式，例如雙特異性T細胞銜接器（BiTEs）、交叉單株抗體（CrossMabs）和DVD-Igs。這些創新提高了抗體的生產性能、穩定性和療效，為更廣泛的臨床研發奠定了基礎。

同時，投資者對生物製藥領域的興趣和資金籌措不斷增加，推動了雙特異性抗體研發的擴張。在創業投資和策略合作的支持下，成熟的製藥公司和生技新興企業都在增加對該領域的投資。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構在審查新型生物製藥時也展現出彈性，有助於縮短研發週期，並加速雙特異性療法的市場進入。

與傳統治療方法相比，標靶性強、個人化的療法療效較佳，患者對此越來越接受。雙特異性抗體通常具有脫靶毒性低、免疫介導的癌細胞殺傷作用強等優點，進一步促進了其臨床應用。

摘要，雙特異性抗體療法市場受到未被滿足的需求、日趨成熟的技術、強力的資金支持和有利的法規環境的驅動，這些因素共同造就了一個快速成長且具有高潛力的治療領域。

主要企業包括羅氏、安進、賽諾菲、輝瑞和強生。全球前五名生產商佔了超過95%的市場。北美是最大的市場，約佔65%的佔有率，其次是歐洲和中國，各佔30%以上的佔有率。依產品類型分類，IgG類抗體是最大的區隔市場，佔85%以上的市佔率。按應用領域分類，血友病是最大的應用領域，其次是腫瘤治療和其他治療。

本報告旨在按地區/國家、類型和應用對全球雙特異性抗體療法市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以銷售收入為指標，對雙特異性抗體療法市場規模、估算和預測進行了呈現，以2024年為基準年，並涵蓋了2020年至2031年的歷史數據和預測數據。報告結合定量和定性分析，旨在幫助讀者制定雙特異性抗體療法的業務和成長策略，評估市場競爭，分析公司在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Roche
  • Amgen
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • AbbVie
  • Lindis Biotech
  • MacroGenics, Inc
  • Genmab
  • Alphamab Co. Ltd
  • Akeso, Inc.

按類型分類的區隔市場

  • 基於片段的抗體
  • 基於IgG的抗體

應用領域

  • 癌症
  • 血友病
  • 其他非癌症疾病

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Bi-Specific Antibodies Therapy was estimated to be worth US$ 4165 million in 2024 and is forecast to a readjusted size of US$ 18056 million by 2031 with a CAGR of 23.4% during the forecast period 2025-2031.

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

The growth of the bispecific antibody therapy market is driven by a combination of rising clinical demand, technological advancements, investment momentum, and regulatory support. One of the primary drivers is the increasing global incidence of cancer-particularly hematological malignancies and treatment-resistant solid tumors-which has created a strong demand for more precise and effective immunotherapies. Bispecific antibodies, with their ability to simultaneously target two different antigens, offer enhanced specificity and immune activation, positioning them as a promising next-generation therapeutic approach in oncology.

Advancements in biotechnology and antibody engineering have significantly accelerated the development of bispecific platforms. Historically, challenges such as structural complexity, poor stability, and low manufacturing yield limited their progress. However, breakthroughs in protein design, expression systems, and drug delivery technologies have enabled the emergence of clinically viable formats such as BiTEs (bispecific T-cell engagers), CrossMabs, and DVD-Igs. These innovations have improved manufacturability, stability, and efficacy, paving the way for a broader clinical pipeline.

In parallel, growing investor interest and funding in the biopharmaceutical sector have fueled the expansion of bispecific antibody R\&D. Both established pharmaceutical companies and biotech startups are increasingly investing in this field, supported by active venture capital and strategic partnerships. Regulatory bodies like the FDA and EMA are also showing flexibility in reviewing novel biologics, facilitating faster development timelines and market access for bispecific therapies.

On the patient side, there is increasing acceptance of targeted, personalized treatments that offer superior outcomes compared to traditional therapies. Bispecific antibodies often demonstrate reduced off-target toxicity and enhanced immune-mediated tumor cell killing, further driving clinical adoption.

In summary, the bispecific antibody therapy market is being propelled by unmet clinical needs, technological maturation, strong financial backing, and a favorable regulatory environment-factors that together are shaping a rapidly growing and high-potential therapeutic space.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%. North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Bi-Specific Antibodies Therapy by region & country, by Type, and by Application.

The Bi-Specific Antibodies Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy.

Market Segmentation

By Company

  • Roche
  • Amgen
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • AbbVie
  • Lindis Biotech
  • MacroGenics, Inc
  • Genmab
  • Alphamab Co. Ltd
  • Akeso, Inc.

Segment by Type

  • Fragment-Based Antibodies
  • IgG-Based Antibodies

Segment by Application

  • Cancer
  • Haemophilia
  • Other Non-Cancer Diseases

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Bi-Specific Antibodies Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Bi-Specific Antibodies Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Bi-Specific Antibodies Therapy Product Introduction
  • 1.2 Global Bi-Specific Antibodies Therapy Market Size Forecast (2020-2031)
  • 1.3 Bi-Specific Antibodies Therapy Market Trends & Drivers
    • 1.3.1 Bi-Specific Antibodies Therapy Industry Trends
    • 1.3.2 Bi-Specific Antibodies Therapy Market Drivers & Opportunity
    • 1.3.3 Bi-Specific Antibodies Therapy Market Challenges
    • 1.3.4 Bi-Specific Antibodies Therapy Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Bi-Specific Antibodies Therapy Players Revenue Ranking (2024)
  • 2.2 Global Bi-Specific Antibodies Therapy Revenue by Company (2020-2025)
  • 2.3 Key Companies Bi-Specific Antibodies Therapy Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Bi-Specific Antibodies Therapy Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Bi-Specific Antibodies Therapy
  • 2.6 Bi-Specific Antibodies Therapy Market Competitive Analysis
    • 2.6.1 Bi-Specific Antibodies Therapy Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Bi-Specific Antibodies Therapy Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Fragment-Based Antibodies
    • 3.1.2 IgG-Based Antibodies
  • 3.2 Global Bi-Specific Antibodies Therapy Sales Value by Type
    • 3.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Bi-Specific Antibodies Therapy Sales Value, by Type (2020-2031)
    • 3.2.3 Global Bi-Specific Antibodies Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Cancer
    • 4.1.2 Haemophilia
    • 4.1.3 Other Non-Cancer Diseases
  • 4.2 Global Bi-Specific Antibodies Therapy Sales Value by Application
    • 4.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Bi-Specific Antibodies Therapy Sales Value, by Application (2020-2031)
    • 4.2.3 Global Bi-Specific Antibodies Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Bi-Specific Antibodies Therapy Sales Value by Region
    • 5.1.1 Global Bi-Specific Antibodies Therapy Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Bi-Specific Antibodies Therapy Sales Value by Region (2020-2025)
    • 5.1.3 Global Bi-Specific Antibodies Therapy Sales Value by Region (2026-2031)
    • 5.1.4 Global Bi-Specific Antibodies Therapy Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.2.2 North America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.3.2 Europe Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Bi-Specific Antibodies Therapy Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.5.2 South America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.3.2 United States Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.4.2 Europe Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.5.2 China Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.6.2 Japan Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.7.2 South Korea Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.9.2 India Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Roche
    • 7.1.1 Roche Profile
    • 7.1.2 Roche Main Business
    • 7.1.3 Roche Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.1.4 Roche Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Roche Recent Developments
  • 7.2 Amgen
    • 7.2.1 Amgen Profile
    • 7.2.2 Amgen Main Business
    • 7.2.3 Amgen Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.2.4 Amgen Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Amgen Recent Developments
  • 7.3 Sanofi
    • 7.3.1 Sanofi Profile
    • 7.3.2 Sanofi Main Business
    • 7.3.3 Sanofi Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.3.4 Sanofi Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Sanofi Recent Developments
  • 7.4 Pfizer
    • 7.4.1 Pfizer Profile
    • 7.4.2 Pfizer Main Business
    • 7.4.3 Pfizer Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.4.4 Pfizer Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Pfizer Recent Developments
  • 7.5 Johnson & Johnson
    • 7.5.1 Johnson & Johnson Profile
    • 7.5.2 Johnson & Johnson Main Business
    • 7.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Johnson & Johnson Recent Developments
  • 7.6 AstraZeneca
    • 7.6.1 AstraZeneca Profile
    • 7.6.2 AstraZeneca Main Business
    • 7.6.3 AstraZeneca Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.6.4 AstraZeneca Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.6.5 AstraZeneca Recent Developments
  • 7.7 AbbVie
    • 7.7.1 AbbVie Profile
    • 7.7.2 AbbVie Main Business
    • 7.7.3 AbbVie Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.7.4 AbbVie Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.7.5 AbbVie Recent Developments
  • 7.8 Lindis Biotech
    • 7.8.1 Lindis Biotech Profile
    • 7.8.2 Lindis Biotech Main Business
    • 7.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Lindis Biotech Recent Developments
  • 7.9 MacroGenics, Inc
    • 7.9.1 MacroGenics, Inc Profile
    • 7.9.2 MacroGenics, Inc Main Business
    • 7.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.9.5 MacroGenics, Inc Recent Developments
  • 7.10 Genmab
    • 7.10.1 Genmab Profile
    • 7.10.2 Genmab Main Business
    • 7.10.3 Genmab Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.10.4 Genmab Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Genmab Recent Developments
  • 7.11 Alphamab Co. Ltd
    • 7.11.1 Alphamab Co. Ltd Profile
    • 7.11.2 Alphamab Co. Ltd Main Business
    • 7.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Alphamab Co. Ltd Recent Developments
  • 7.12 Akeso, Inc.
    • 7.12.1 Akeso, Inc. Profile
    • 7.12.2 Akeso, Inc. Main Business
    • 7.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Akeso, Inc. Recent Developments

8 Industry Chain Analysis

  • 8.1 Bi-Specific Antibodies Therapy Industrial Chain
  • 8.2 Bi-Specific Antibodies Therapy Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Bi-Specific Antibodies Therapy Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Bi-Specific Antibodies Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Bi-Specific Antibodies Therapy Market Trends
  • Table 2. Bi-Specific Antibodies Therapy Market Drivers & Opportunity
  • Table 3. Bi-Specific Antibodies Therapy Market Challenges
  • Table 4. Bi-Specific Antibodies Therapy Market Restraints
  • Table 5. Global Bi-Specific Antibodies Therapy Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Bi-Specific Antibodies Therapy Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Bi-Specific Antibodies Therapy Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Bi-Specific Antibodies Therapy Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Bi-Specific Antibodies Therapy
  • Table 10. Global Bi-Specific Antibodies Therapy Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Bi-Specific Antibodies Therapy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Bi-Specific Antibodies Therapy Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Bi-Specific Antibodies Therapy Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Bi-Specific Antibodies Therapy Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Bi-Specific Antibodies Therapy Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Bi-Specific Antibodies Therapy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Bi-Specific Antibodies Therapy Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Bi-Specific Antibodies Therapy Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Bi-Specific Antibodies Therapy Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Bi-Specific Antibodies Therapy Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Bi-Specific Antibodies Therapy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Bi-Specific Antibodies Therapy Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Bi-Specific Antibodies Therapy Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Bi-Specific Antibodies Therapy Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Bi-Specific Antibodies Therapy Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Roche Basic Information List
  • Table 32. Roche Description and Business Overview
  • Table 33. Roche Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Roche (2020-2025)
  • Table 35. Roche Recent Developments
  • Table 36. Amgen Basic Information List
  • Table 37. Amgen Description and Business Overview
  • Table 38. Amgen Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Amgen (2020-2025)
  • Table 40. Amgen Recent Developments
  • Table 41. Sanofi Basic Information List
  • Table 42. Sanofi Description and Business Overview
  • Table 43. Sanofi Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Sanofi (2020-2025)
  • Table 45. Sanofi Recent Developments
  • Table 46. Pfizer Basic Information List
  • Table 47. Pfizer Description and Business Overview
  • Table 48. Pfizer Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Pfizer (2020-2025)
  • Table 50. Pfizer Recent Developments
  • Table 51. Johnson & Johnson Basic Information List
  • Table 52. Johnson & Johnson Description and Business Overview
  • Table 53. Johnson & Johnson Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Johnson & Johnson (2020-2025)
  • Table 55. Johnson & Johnson Recent Developments
  • Table 56. AstraZeneca Basic Information List
  • Table 57. AstraZeneca Description and Business Overview
  • Table 58. AstraZeneca Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of AstraZeneca (2020-2025)
  • Table 60. AstraZeneca Recent Developments
  • Table 61. AbbVie Basic Information List
  • Table 62. AbbVie Description and Business Overview
  • Table 63. AbbVie Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of AbbVie (2020-2025)
  • Table 65. AbbVie Recent Developments
  • Table 66. Lindis Biotech Basic Information List
  • Table 67. Lindis Biotech Description and Business Overview
  • Table 68. Lindis Biotech Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Lindis Biotech (2020-2025)
  • Table 70. Lindis Biotech Recent Developments
  • Table 71. MacroGenics, Inc Basic Information List
  • Table 72. MacroGenics, Inc Description and Business Overview
  • Table 73. MacroGenics, Inc Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of MacroGenics, Inc (2020-2025)
  • Table 75. MacroGenics, Inc Recent Developments
  • Table 76. Genmab Basic Information List
  • Table 77. Genmab Description and Business Overview
  • Table 78. Genmab Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Genmab (2020-2025)
  • Table 80. Genmab Recent Developments
  • Table 81. Alphamab Co. Ltd Basic Information List
  • Table 82. Alphamab Co. Ltd Description and Business Overview
  • Table 83. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Alphamab Co. Ltd (2020-2025)
  • Table 85. Alphamab Co. Ltd Recent Developments
  • Table 86. Akeso, Inc. Basic Information List
  • Table 87. Akeso, Inc. Description and Business Overview
  • Table 88. Akeso, Inc. Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Akeso, Inc. (2020-2025)
  • Table 90. Akeso, Inc. Recent Developments
  • Table 91. Key Raw Materials Lists
  • Table 92. Raw Materials Key Suppliers Lists
  • Table 93. Bi-Specific Antibodies Therapy Downstream Customers
  • Table 94. Bi-Specific Antibodies Therapy Distributors List
  • Table 95. Research Programs/Design for This Report
  • Table 96. Key Data Information from Secondary Sources
  • Table 97. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Bi-Specific Antibodies Therapy Product Picture
  • Figure 2. Global Bi-Specific Antibodies Therapy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Bi-Specific Antibodies Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Bi-Specific Antibodies Therapy Report Years Considered
  • Figure 5. Global Bi-Specific Antibodies Therapy Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Bi-Specific Antibodies Therapy Revenue in 2024
  • Figure 7. Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Fragment-Based Antibodies Picture
  • Figure 9. IgG-Based Antibodies Picture
  • Figure 10. Global Bi-Specific Antibodies Therapy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Bi-Specific Antibodies Therapy Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Cancer
  • Figure 13. Product Picture of Haemophilia
  • Figure 14. Product Picture of Other Non-Cancer Diseases
  • Figure 15. Global Bi-Specific Antibodies Therapy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Bi-Specific Antibodies Therapy Sales Value Market Share by Application, 2024 & 2031
  • Figure 17. North America Bi-Specific Antibodies Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 18. North America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 19. Europe Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 20. Europe Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Asia Pacific Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Asia Pacific Bi-Specific Antibodies Therapy Sales Value by Region (%), 2024 VS 2031
  • Figure 23. South America Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. South America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Middle East & Africa Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. Middle East & Africa Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value (%), (2020-2031)
  • Figure 28. United States Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. United States Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 30. United States Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 31. Europe Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Europe Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 33. Europe Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 34. China Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. China Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 36. China Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 37. Japan Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Japan Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 39. Japan Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 40. South Korea Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. South Korea Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 42. South Korea Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Southeast Asia Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 46. India Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. India Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 48. India Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 49. Bi-Specific Antibodies Therapy Industrial Chain
  • Figure 50. Bi-Specific Antibodies Therapy Manufacturing Cost Structure
  • Figure 51. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 52. Bottom-up and Top-down Approaches for This Report
  • Figure 53. Data Triangulation
  • Figure 54. Key Executives Interviewed